To hear about similar clinical trials, please enter your email below
Trial Title:
Attenuation of the Hemodynamic Response to Double-lumen Endotracheal Intubation With Nebulized Lidocaine
NCT ID:
NCT05850702
Condition:
Lung Neoplasms
Conditions: Official terms:
Lung Neoplasms
Lidocaine
Conditions: Keywords:
Double-lumen Endotracheal Intubation
Study type:
Interventional
Study phase:
Phase 4
Overall status:
Not yet recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Prevention
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Intervention:
Intervention type:
Drug
Intervention name:
Lidocaine
Description:
inhale 5ml of 2% lidocaine by nebulization
Arm group label:
lidocaine
Intervention type:
Drug
Intervention name:
Saline
Description:
inhale 5ml of saline by nebulization
Arm group label:
saline
Summary:
The goal of this clinical trial is to test the effect of nebulized lidocaine on the
hemodynamic response in the participant undergoing double-lumen endotracheal intubation.
The main question it aims to answer is to evaluate the changes in mean arterial pressure
after intubation.
Participants will inhale 5ml of 2% lidocaine by nebulization15min before intubation.
Researchers will compare saline group to see if saline effects
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. aged 18-65 years, American Society of Anesthesiologists class I-II
2. participants undergoing double-lumen endotracheal intubation under general
anesthesia
3. signed informed consent and volunteered to participate in the experiment
Exclusion Criteria:
1. Poor control of hypertension
2. preoperative arrhythmia
3. severe coronary artery or heart valve disease
4. sequelae of cerebrovascular accident
5. severe lung, liver, kidney and immune system diseases
6. Suspected difficult airway
7. confirmed or suspected allergy to this trial drug
8. As judged by the investigator to be ineligible for the study, such as communication
impairment (language or intelligence)
Gender:
All
Minimum age:
18 Years
Maximum age:
65 Years
Healthy volunteers:
No
Start date:
June 15, 2023
Completion date:
September 9, 2025
Lead sponsor:
Agency:
RenJi Hospital
Agency class:
Other
Source:
RenJi Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05850702
